Proton pump inhibitors therapy and risk of hip fracture: A systematic review and meta-analysis

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 9, 2011, Pages 794-800

  Ye, Xiaofei ^a   Liu, Hong ^a   Wu, Cheng ^a   Qin, Yingyi ^a   Zang, Jiajie ^a   Gao, Qingbin ^a   Zhang, Xinji ^a   He, Jia ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; LEMINOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE;

CANADA; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; DENMARK; EUROPE; HIP FRACTURE; HUMAN; META ANALYSIS; NETHERLANDS; NORTH AMERICA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; HIP FRACTURES; HUMANS; MIDDLE AGED; PROTON PUMP INHIBITORS; RESEARCH DESIGN; RISK ASSESSMENT; YOUNG ADULT;

EID: 80051790502     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328348a56a     Document Type: Review

References (34)

1. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety. Pharmacol Res 2009;59:135-153.
2. Teramura-Gronblad M, Hosia-Randell H, Muurinen S, Pitkala K. Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care 2010;28:154-159.
3. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acidsuppressive drugs. JAMA 2004;292:1955-1960. (Pubitemid 39411203)
4. Harmark L, Van der Wiel HE, de Groot MC, Van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol 2007;64:819-823. (Pubitemid 350222055)
5. Lobera T, Navarro B, Del Pozo MD, González I, Blasco A, Escudero R, et al. Nine cases of omeprazole allergy: cross-reactivity between proton pump inhibitors. J Investig Allergol Clin Immunol 2009;19:57-60.
6. Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000;50:366-372.
7. Lodato F, Azzaroli F, Turco L, Mazzella N, Buonfiglioli F, Zoli M, Mazzella G. Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol 2010;24:193-201.
8. Voelker R. Proton pump inhibitors linked to fracture risk. JAMA 2010;304:29.
9. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-1733. (Pubitemid 44607392)
10. Parker M, Johansen A. Hip fracture. BMJ 2006;333:27-30. (Pubitemid 44406843)
11. Cumming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. Epidemiol Rev 1997;19:244-257. (Pubitemid 28099774)
12. Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 2002;50:1644-1650. (Pubitemid 35192535)
13. Sheikh MS, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 1987;317:532-536. (Pubitemid 17123269)
14. Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2011;22:903-910.
15. Chonan O, Takahashi R, Yasui H, Watanuki M. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo) 1998;44:473-481. (Pubitemid 28370958)
16. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005;118:778-781. (Pubitemid 40897665)
17. Gendreau-Webb R. Bone up on proton pump inhibitors and fracture risk. Nursing 2007;37:60-61.
18. Laine L. Proton pump inhibitors and bone fractures? Am J Gastroenterol 2009;104(Suppl 2):S21-S26.
19. Moayyedi PCommittee CAGCA. Hip fracture and proton pump inhibitor therapy: position statement. Can J Gastroenterol 2008;22:855-858.
20. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012. (Pubitemid 30214957)
21. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010;139:93-101.
22. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010;170:765-771.
23. De Vries F, Cooper AL, Cockle SM, Van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009;20:1989-1998.
24. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010;138:896-904.
25. Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83:251-259.
26. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83. (Pubitemid 44306164)
27. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke: a meta-analysis. JAMA 2003;289:579-588. (Pubitemid 37428630)
28. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-326.
29. De Vries F, Van Staa TP, Leufkens HG. Proton pump inhibitors, fracture risk and selection bias: three studies, same database, two answers. Osteoporos Int 2011;22:1641-1642.
30. Serfaty-Lacrosniere C, Wood RJ, Voytko D, Saltzman JR, Pedrosa M, Sepe TE, Russell RR. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995;14:364-368.
31. Zaidi M. Modularity of osteoclast behaviour and 'mode-specific' inhibition of osteoclast function. Biosci Rep 1990;10:547-556.
32. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951-959.
33. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-2953. (Pubitemid 46021498)
34. Richards JB, Goltzman D. Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ 2008;179:306-307.